PO-1689 Potential NTCP reductions for high-risk prostate cancer patients by MR-guided adaptive radiotherapy. (May 2022) - Christiansen, R.L.; Dysager, L.; Hansen, C.R.; Schytte, T.; Bertelsen, A.S.; Jensen, H.R.; Mahmood, F.; Nyborg, C.J.; Hansen, S.; Agergaard, S.N.; Hansen, O.; Brink, C.; et al.